Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Foodand DrugAdministration Thursday approved a new kind of drug. Studies ...
Some results have been hidden because they may be inaccessible to you